Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

20.74 -0.63 (-2.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 663,450
Open 21.78
Bid (Size) 20.50 (1)
Ask (Size) 30.00 (1)
Prev. Close 21.37
Today's Range 20.04 - 22.52
52wk Range 13.30 - 30.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga

Performance

YTD
-13.2%
-13.2%
1 Month
+5.3%
+5.3%
3 Month
-3.4%
-3.4%
6 Month
-10.8%
-10.8%
1 Year
+1.5%
+1.5%

More News

Read More
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Via Benzinga
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Via Benzinga
Wall Street Mixed As Tech Stocks Fall, Fed Meeting Begins
Via Talk Markets
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
Via InvestorPlace
Bears Reload On Mobileye After Sharp Gains In Stock Price
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
Via Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
Via Benzinga

Frequently Asked Questions

Is Enliven Therapeutics, Inc. - Common Stock publicly traded?
Yes, Enliven Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Enliven Therapeutics, Inc. - Common Stock trade on?
Enliven Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enliven Therapeutics, Inc. - Common Stock?
The ticker symbol for Enliven Therapeutics, Inc. - Common Stock is ELVN on the Nasdaq Stock Market
What is the current price of Enliven Therapeutics, Inc. - Common Stock?
The current price of Enliven Therapeutics, Inc. - Common Stock is 20.74
When was Enliven Therapeutics, Inc. - Common Stock last traded?
The last trade of Enliven Therapeutics, Inc. - Common Stock was at 06/06/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.